View Future GrowthAlamar Biosciences 과거 순이익 실적과거 기준 점검 0/6Alamar Biosciences 의 수입은 연평균 -3%의 비율로 감소해 온 반면, Life Sciences 산업은 연평균 3.7%의 비율로 감소했습니다. 매출은 연평균 134%의 비율로 증가해 왔습니다.핵심 정보-3.01%순이익 성장률6.69%주당순이익(EPS) 성장률Life Sciences 산업 성장률21.51%매출 성장률134.03%자기자본이익률-76.39%순이익률-49.89%다음 순이익 업데이트10 Aug 2026최근 과거 실적 업데이트공고 • Jul 15Alamar Biosciences, Inc. to Report Q2, 2026 Results on Aug 10, 2026Alamar Biosciences, Inc. announced that they will report Q2, 2026 results After-Market on Aug 10, 2026Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.공고 • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026모든 업데이트 보기Recent updates실시간 뉴스 • 10hAlamar Biosciences Unveils NULISAseq Immune 340 Panel for Expanded Disease ResearchAlamar Biosciences launched the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling product so far, enabling measurement of about 340 immune-related proteins from a single sample for translational research and drug development. The new panel extends the earlier NULISAseq Inflammation Panel 250 and is aimed at research in cancer, cardiovascular and metabolic diseases, autoimmune conditions, and aging. This broadens the range of disease areas addressable on Alamar’s platform. Alamar Biosciences shares recently traded at about US$24.37, with the stock down roughly 12.2% over the past 30 days. This launch signals that Alamar Biosciences is investing in a wider suite of immune proteome tools, which could deepen adoption among researchers focused on complex disease biology. From an investment perspective, a richer panel may help the company capture more workflows within existing customers and appeal to new labs that need high-plex immune profiling, although actual commercial traction and pricing will be important factors to monitor.공고 • 23hAlamar Biosciences Launches NULISAseq Immune 340 Panel For Comprehensive Profiling Of The Immune ProteomeAlamar Biosciences, Inc. announced the launch of the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling solution available for translational research and drug development. The panel expands on the NULISAseq Inflammation Panel 250, to deliver simultaneous measurement of approximately 340 immune-related proteins from a single sample. By measuring key proteins that were previously undetectable by other methods, the Immune 340 Panel deepens the understanding of the immune proteome in critical disease areas across cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging research. Highly sensitive multiplex measurement captures regulatory proteins, like checkpoint inhibitors, and low abundance targets that standard platforms routinely miss. Immune responses are never driven by a single protein. Pathway crosstalk, feedback loops, and cell type cooperation all demand multi-protein context to interpret. Understanding this biology, and catching it early, requires measuring the cytokines and other biomarkers of immune activation that signal disease before symptoms appear. The challenge is detection. Many immune mediators, including cytokines, chemokines, and cell death pathway markers, circulate at fg/mL to sub-pg/mL concentrations, well below the floor of conventional immunoassays. This is especially true of inflammaging, the chronic, low-grade inflammation that builds quietly with age as immune senescence and neuroimmune activation compound to drive cardiovascular, metabolic, neurodegenerative, and cancer risk. Its key signals have largely been invisible to researchers until now. In drug development, the ability to simultaneously profile the full immune landscape – not just the well-characterized cytokines, but the entire network of checkpoints, metabolic regulators, cell death mediators, and co-stimulatory signals – fundamentally changes what can be learned from a single sample. What makes the NULISAseq Immune 340 Panel distinctive is the combination of breadth and sensitivity. Many of the proteins most relevant to immune mechanisms of action, resistance, and toxicity have historically been undetectable in blood. Having access to them, alongside the canonical markers, in one multiplexed run opens new possibilities for biomarker discovery and patient stratification.실시간 뉴스 • Jul 25Alamar Biosciences Secures Rights to Use pTau217 Antibody in Alzheimer’s DiagnosticsALZpath and Alamar Biosciences have expanded their agreement to cover clinical diagnostics, granting Alamar commercial rights to use ALZpath’s proprietary pTau217 antibody in blood-based tests intended for Alzheimer’s disease diagnosis. The broadened deal allows Alamar to apply the pTau217 antibody in both research and clinical environments, which could support wider use of blood biomarkers as an alternative to more invasive or complex Alzheimer’s diagnostic tools. Alamar Biosciences’ stock trades at $25.88, with the share price up 17.6% year to date. Bringing a clinically focused pTau217 antibody into Alamar Biosciences’ test line-up could strengthen its position in Alzheimer’s diagnostics, but it also raises execution questions around assay performance, regulatory pathways and eventual clinical uptake that readers may wish to factor into their risk view.공고 • Jul 16Alamar Biosciences, Inc. Announces Board and Committee ChangesAlamar Biosciences, Inc. was deeply saddened to report that Ian Ratcliffe, a member of the Company's board of directors, passed away on July 5, 2026. Ian Ratcliffe served as an independent director on the Board since February 2024. Following Ian Ratcliffe's passing, the Board decreased the number of authorized directors constituting the full Board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the Board.공고 • Jul 15Alamar Biosciences, Inc. to Report Q2, 2026 Results on Aug 10, 2026Alamar Biosciences, Inc. announced that they will report Q2, 2026 results After-Market on Aug 10, 2026실시간 뉴스 • Jul 14Alamar Biosciences Joins Major University Effort on Nationwide Neurodegenerative Biomarker StudyAlamar Biosciences is partnering with leading research universities on a national proteomics initiative that will use its NULISAseq Neuro 220 panel to profile about 21,000 plasma samples from 10,000 participants for blood-based biomarkers linked to Alzheimer’s and other neurodegenerative diseases. The project will create a large, publicly accessible dataset tied to National Alzheimer’s Coordinating Center IDs and is part of Alamar’s CLARiTI portfolio, with plans for a national AI-focused data challenge to support discovery. Alamar Biosciences shares trade at US$27.40, with the stock up 24.5% over the past 30 days. Having its Neuro 220 panel embedded in a national, open-data effort could help Alamar Biosciences build credibility in neurobiology tools and AI-driven biomarker discovery, while also exposing the platform to a broad base of academic and clinical users.공고 • Jul 13Alamar Biosciences Partners With Research Universities To Launch National Proteomics Initiative Using NULISAseq Neuro 220 PanelAlamar Biosciences partnered with research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarker discovery and validation for Alzheimer’s disease and related neurodegenerative conditions. The project is co-led by professors Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin; and Tatiana Foroud, PhD, director of the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) at Indiana University. The project will generate large-scale plasma proteomic data from approximately 21,000 samples collected from 10,000 Alzheimer’s Disease Research Center (ADRC) participants across the United States. Samples are stored at NCRAD, providing a centralized national infrastructure for coordinated access and biomarker generation at scale. Profiling will use Alamar Biosciences’ NULISAseq Neuro 220 panel, enhanced with a newly added eMTBR-Tau assay that enables simultaneous blood-based representation of tau tangle burden alongside a broad panel of neurodegeneration and neuroinflammation biomarkers. The panel also offers the largest number of brain-derived Tau targets along with assays relevant to alpha-synuclein biology and other protein aggregation markers, creating a unique opportunity to study multiple neurodegenerative disease pathways in the same deeply characterized participants. The project is part of the CLARiTI portfolio and leverages its infrastructure to support coordinated sample access and harmonized data workflows. The effort has been advanced through sustained partnerships with the Alzheimer’s Association, the Robertson Foundation, an anonymous foundation, and important implementation and data-sharing support from the Alzheimer’s Disease Data Initiative. All data generated through the initiative will be made freely available to the global research community. A central goal is the creation of an open, publicly accessible proteomic dataset linked to National Alzheimer’s Coordinating Center (NACC) IDs. This linkage will allow researchers to connect the new proteomic profiles with rich longitudinal data available through the ADRC Program, including clinical, cognitive, neuroimaging, genetic, genomic, fluid biomarker, and neuropathology data. AI and computational teams will apply multimodal approaches for disease classification, biomarker discovery, and prediction of neurodegenerative disease progression. The next phase of the project will include a national data challenge inviting the broader research community to develop and test new analytical methods using this resource.실시간 뉴스 • Jul 08Alamar Biosciences Unveils First Multiplexed Immunoassay Targeting Alzheimer’s eMTBR-Tau BiomarkerAlamar Biosciences has launched the first commercial multiplexed blood-based immunoassay for the Alzheimer’s biomarker eMTBR-Tau, available within its NULISAseq Neuro 220 panel kits and as a single-plex test through its Technology Access Program, with new clinical data slated for presentation at AAIC 2026. The eMTBR-Tau assay targets a plasma biomarker tied to tau tangle pathology and Alzheimer’s progression, expanding Alamar Biosciences’ neuro-focused offering and providing researchers with a more precise tool to measure disease-related tau biology. Alamar Biosciences’ stock trades at $25.23, with the share price up 22.8% over the past 30 days. This launch puts more attention on Alamar Biosciences’ role in Alzheimer’s research tools, and investor outcomes will depend on how widely researchers and partners adopt the eMTBR-Tau assay and whether it leads to durable assay demand.공고 • Jul 08Alamar Biosciences Launches the First Multiplexed Blood-Based Immunoassay for eMTBR-TauAlamar Biosciences, Inc. launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq Neuro 220 multiplexed panel kits, deployable on the entire installed base of ARGO HT instruments, and as a single-plex assay through the company’s Technology Access Program. The assay measures eMTBR-Tau, a plasma biomarker that specifically reflects tau tangle pathology and has demonstrated strong associations with cognitive decline, clinical disease staging, and therapeutic response monitoring for Alzheimer’s disease. Immunoassay for eMTBR-Tau is available in the NULISAseq Neuro 220 panel and as a single-plex assay through the Technology Access Program. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease. A definitive diagnosis of Alzheimer’s disease requires evidence of two hallmark pathologies: amyloid plaques and tau neurofibrillary tangles. Until recently, only one of these could be measured in blood: pTau-217, which serves as an indicator of amyloid pathology. However, a positive pTau-217 result alone is insufficient for a confirmatory diagnosis, as many individuals with amyloid accumulation have not yet developed tau tangles. Historically, measuring tau tangle burden required tau PET imaging, a method that is accurate but expensive and operationally complex. Recent studies have shown that a blood-based eMTBR-tau243 assay, based on mass spectrometry, correlates strongly with tau tangle burden, making it a promising blood-based surrogate for tau PET imaging. Alamar’s NULISA platform delivers a broadly accessible eMTBR-Tau assay that specifically targets the MTBR fragment that is generated by endogenous cleavage at site 256. The highly scalable assay measures eMTBR-Tau at attomolar sensitivity, multiplexed with other key neurodegeneration and neuroinflammation biomarkers from a single low volume sample. Beyond diagnosis, the close association between eMTBR-Tau levels and tau tangle burden may allow researchers to directly measure biological response to tau-targeted therapies and address a critical unmet need for a blood-based biomarker of treatment efficacy. Alamar will showcase eMTBR-Tau data at its workshop at the Alzheimer’s Association International Conference 2026 in London on Tuesday, July 14, where researchers will present performance results and clinical findings from studies using the NULISA platform. The workshop will include presentations covering the assay’s analytical performance, correlation with tau PET imaging, and the ability to stratify patients across Alzheimer’s disease stages. The NULISAseq Neuro 220 Panel with eMTBR-Tau is available now.공고 • Jun 03Alamar Biosciences Launches Nulisa Dried Blood Spot Extraction KitAlamar Biosciences, Inc. launched the NULISA Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices. Dried blood spot sampling turns a few drops of blood into a dried, ambient-shippable specimen. For proteomics, it has been challenging for researchers to recover protein signals from extremely small sample volumes, across different collection devices, without losing the low-abundance biology they are trying to measure. The NULISA DBS Extraction Kit addresses these challenges with a standardized workflow for multiplex protein measurement from blood samples, collected on remote sampling devices and shipped at ambient temperature. The workflow connects remote sample collection to Alamar’s NULISA technology, enabling ultra-sensitive detection of low-abundance protein biomarkers in non-invasive biofluids. The NULISA platform offers ultra-high sensitivity, high specificity, flexible multiplexing, a broad dynamic range, and automated workflows. In validation studies, Alamar demonstrated 85–95% target detectability across its NULISA CNS and Inflammation panels on most supported microsampling platforms. The combination of the ARGO HT instrument design and the simplified collection and transport of dried blood spot microsamples unlocks proteomics in settings where it hasn't been practical, such as specialty clinics, regional labs, and point-of-care environments. The NULISA DBS Extraction Kit standardizes protein extraction across dried blood spot and dried plasma spot microsamples collected on leading third-party microsampling devices, including Capitainer, Telimmune, Mitra, and Tasso. The NULISA DBS Extraction Kit is now available.New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years).Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.실시간 뉴스 • May 10Alamar Biosciences Launches Home Fingerstick Kit for Ultra Sensitive Multiplex Proteomics AssaysAlamar Biosciences launched the NULISA Dried Blood Spot (DBS) Extraction Kit, allowing its ultra high-sensitivity, multiplex proteomics assays to run on small fingerstick blood samples collected at home. The kit is designed to support longitudinal and decentralized translational studies in neurology, inflammation and population health. The company positions this DBS capability as a way to make proteomics more accessible for population-based screening programs and remote sample collection. This move pushes Alamar’s platform further into remote and decentralized research workflows, which can matter for adoption by academic centers, contract research groups and potential biopharma partners. Investors may want to watch how quickly the DBS kit is incorporated into real-world studies, since usage levels and reference customers could become key indicators of commercial traction for Alamar’s technology.공고 • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026Seeking Alpha • Apr 19Alamar Biosciences: Looking For An Early DetectionSummary Alamar Biosciences surged 30% post-IPO, driven by enthusiasm for its precision proteomics technology targeting early disease detection. Alamar's revenue nearly tripled to $74M in 2025, with annualized sales multiples now around 12x; losses narrowed but remain substantial. Strong cash reserves and rapid topline growth offset concerns about ongoing losses and operating deleverage. I remain on the sidelines, closely monitoring future topline and bottom-line trends before considering a position. Read the full article on Seeking Alpha공고 • Apr 18Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million.Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Sponsor Backed Offering매출 및 비용 세부 내역Alamar Biosciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGS:ALMR 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2687-43434231 Dec 2574-30363731 Dec 2425-461939양질의 수익: ALMR 은(는) 현재 수익성이 없습니다.이익 마진 증가: ALMR는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ALMR은 상장된 지 3년이 되지 않아 지난 5년간 전년 대비 수익 증가율이 긍정적인지 확인할 수 없습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ALMR의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ALMR은 수익성이 없어 지난 해 수익 성장률을 Life Sciences 업계(12.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ALMR는 현재 수익성이 없으므로 자본 수익률이 음수(-76.39%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/29 06:21종가2026/07/29 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Alamar Biosciences, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael RyskinBofA Global ResearchCasey WoodringJ.P. MorganPuneet SoudaLeerink Partners LLC2명의 분석가 더 보기
공고 • Jul 15Alamar Biosciences, Inc. to Report Q2, 2026 Results on Aug 10, 2026Alamar Biosciences, Inc. announced that they will report Q2, 2026 results After-Market on Aug 10, 2026
Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.
공고 • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026
실시간 뉴스 • 10hAlamar Biosciences Unveils NULISAseq Immune 340 Panel for Expanded Disease ResearchAlamar Biosciences launched the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling product so far, enabling measurement of about 340 immune-related proteins from a single sample for translational research and drug development. The new panel extends the earlier NULISAseq Inflammation Panel 250 and is aimed at research in cancer, cardiovascular and metabolic diseases, autoimmune conditions, and aging. This broadens the range of disease areas addressable on Alamar’s platform. Alamar Biosciences shares recently traded at about US$24.37, with the stock down roughly 12.2% over the past 30 days. This launch signals that Alamar Biosciences is investing in a wider suite of immune proteome tools, which could deepen adoption among researchers focused on complex disease biology. From an investment perspective, a richer panel may help the company capture more workflows within existing customers and appeal to new labs that need high-plex immune profiling, although actual commercial traction and pricing will be important factors to monitor.
공고 • 23hAlamar Biosciences Launches NULISAseq Immune 340 Panel For Comprehensive Profiling Of The Immune ProteomeAlamar Biosciences, Inc. announced the launch of the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling solution available for translational research and drug development. The panel expands on the NULISAseq Inflammation Panel 250, to deliver simultaneous measurement of approximately 340 immune-related proteins from a single sample. By measuring key proteins that were previously undetectable by other methods, the Immune 340 Panel deepens the understanding of the immune proteome in critical disease areas across cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging research. Highly sensitive multiplex measurement captures regulatory proteins, like checkpoint inhibitors, and low abundance targets that standard platforms routinely miss. Immune responses are never driven by a single protein. Pathway crosstalk, feedback loops, and cell type cooperation all demand multi-protein context to interpret. Understanding this biology, and catching it early, requires measuring the cytokines and other biomarkers of immune activation that signal disease before symptoms appear. The challenge is detection. Many immune mediators, including cytokines, chemokines, and cell death pathway markers, circulate at fg/mL to sub-pg/mL concentrations, well below the floor of conventional immunoassays. This is especially true of inflammaging, the chronic, low-grade inflammation that builds quietly with age as immune senescence and neuroimmune activation compound to drive cardiovascular, metabolic, neurodegenerative, and cancer risk. Its key signals have largely been invisible to researchers until now. In drug development, the ability to simultaneously profile the full immune landscape – not just the well-characterized cytokines, but the entire network of checkpoints, metabolic regulators, cell death mediators, and co-stimulatory signals – fundamentally changes what can be learned from a single sample. What makes the NULISAseq Immune 340 Panel distinctive is the combination of breadth and sensitivity. Many of the proteins most relevant to immune mechanisms of action, resistance, and toxicity have historically been undetectable in blood. Having access to them, alongside the canonical markers, in one multiplexed run opens new possibilities for biomarker discovery and patient stratification.
실시간 뉴스 • Jul 25Alamar Biosciences Secures Rights to Use pTau217 Antibody in Alzheimer’s DiagnosticsALZpath and Alamar Biosciences have expanded their agreement to cover clinical diagnostics, granting Alamar commercial rights to use ALZpath’s proprietary pTau217 antibody in blood-based tests intended for Alzheimer’s disease diagnosis. The broadened deal allows Alamar to apply the pTau217 antibody in both research and clinical environments, which could support wider use of blood biomarkers as an alternative to more invasive or complex Alzheimer’s diagnostic tools. Alamar Biosciences’ stock trades at $25.88, with the share price up 17.6% year to date. Bringing a clinically focused pTau217 antibody into Alamar Biosciences’ test line-up could strengthen its position in Alzheimer’s diagnostics, but it also raises execution questions around assay performance, regulatory pathways and eventual clinical uptake that readers may wish to factor into their risk view.
공고 • Jul 16Alamar Biosciences, Inc. Announces Board and Committee ChangesAlamar Biosciences, Inc. was deeply saddened to report that Ian Ratcliffe, a member of the Company's board of directors, passed away on July 5, 2026. Ian Ratcliffe served as an independent director on the Board since February 2024. Following Ian Ratcliffe's passing, the Board decreased the number of authorized directors constituting the full Board to five and appointed Nicholas Naclerio, Ph.D., to the Audit Committee of the Board.
공고 • Jul 15Alamar Biosciences, Inc. to Report Q2, 2026 Results on Aug 10, 2026Alamar Biosciences, Inc. announced that they will report Q2, 2026 results After-Market on Aug 10, 2026
실시간 뉴스 • Jul 14Alamar Biosciences Joins Major University Effort on Nationwide Neurodegenerative Biomarker StudyAlamar Biosciences is partnering with leading research universities on a national proteomics initiative that will use its NULISAseq Neuro 220 panel to profile about 21,000 plasma samples from 10,000 participants for blood-based biomarkers linked to Alzheimer’s and other neurodegenerative diseases. The project will create a large, publicly accessible dataset tied to National Alzheimer’s Coordinating Center IDs and is part of Alamar’s CLARiTI portfolio, with plans for a national AI-focused data challenge to support discovery. Alamar Biosciences shares trade at US$27.40, with the stock up 24.5% over the past 30 days. Having its Neuro 220 panel embedded in a national, open-data effort could help Alamar Biosciences build credibility in neurobiology tools and AI-driven biomarker discovery, while also exposing the platform to a broad base of academic and clinical users.
공고 • Jul 13Alamar Biosciences Partners With Research Universities To Launch National Proteomics Initiative Using NULISAseq Neuro 220 PanelAlamar Biosciences partnered with research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarker discovery and validation for Alzheimer’s disease and related neurodegenerative conditions. The project is co-led by professors Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin; and Tatiana Foroud, PhD, director of the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) at Indiana University. The project will generate large-scale plasma proteomic data from approximately 21,000 samples collected from 10,000 Alzheimer’s Disease Research Center (ADRC) participants across the United States. Samples are stored at NCRAD, providing a centralized national infrastructure for coordinated access and biomarker generation at scale. Profiling will use Alamar Biosciences’ NULISAseq Neuro 220 panel, enhanced with a newly added eMTBR-Tau assay that enables simultaneous blood-based representation of tau tangle burden alongside a broad panel of neurodegeneration and neuroinflammation biomarkers. The panel also offers the largest number of brain-derived Tau targets along with assays relevant to alpha-synuclein biology and other protein aggregation markers, creating a unique opportunity to study multiple neurodegenerative disease pathways in the same deeply characterized participants. The project is part of the CLARiTI portfolio and leverages its infrastructure to support coordinated sample access and harmonized data workflows. The effort has been advanced through sustained partnerships with the Alzheimer’s Association, the Robertson Foundation, an anonymous foundation, and important implementation and data-sharing support from the Alzheimer’s Disease Data Initiative. All data generated through the initiative will be made freely available to the global research community. A central goal is the creation of an open, publicly accessible proteomic dataset linked to National Alzheimer’s Coordinating Center (NACC) IDs. This linkage will allow researchers to connect the new proteomic profiles with rich longitudinal data available through the ADRC Program, including clinical, cognitive, neuroimaging, genetic, genomic, fluid biomarker, and neuropathology data. AI and computational teams will apply multimodal approaches for disease classification, biomarker discovery, and prediction of neurodegenerative disease progression. The next phase of the project will include a national data challenge inviting the broader research community to develop and test new analytical methods using this resource.
실시간 뉴스 • Jul 08Alamar Biosciences Unveils First Multiplexed Immunoassay Targeting Alzheimer’s eMTBR-Tau BiomarkerAlamar Biosciences has launched the first commercial multiplexed blood-based immunoassay for the Alzheimer’s biomarker eMTBR-Tau, available within its NULISAseq Neuro 220 panel kits and as a single-plex test through its Technology Access Program, with new clinical data slated for presentation at AAIC 2026. The eMTBR-Tau assay targets a plasma biomarker tied to tau tangle pathology and Alzheimer’s progression, expanding Alamar Biosciences’ neuro-focused offering and providing researchers with a more precise tool to measure disease-related tau biology. Alamar Biosciences’ stock trades at $25.23, with the share price up 22.8% over the past 30 days. This launch puts more attention on Alamar Biosciences’ role in Alzheimer’s research tools, and investor outcomes will depend on how widely researchers and partners adopt the eMTBR-Tau assay and whether it leads to durable assay demand.
공고 • Jul 08Alamar Biosciences Launches the First Multiplexed Blood-Based Immunoassay for eMTBR-TauAlamar Biosciences, Inc. launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq Neuro 220 multiplexed panel kits, deployable on the entire installed base of ARGO HT instruments, and as a single-plex assay through the company’s Technology Access Program. The assay measures eMTBR-Tau, a plasma biomarker that specifically reflects tau tangle pathology and has demonstrated strong associations with cognitive decline, clinical disease staging, and therapeutic response monitoring for Alzheimer’s disease. Immunoassay for eMTBR-Tau is available in the NULISAseq Neuro 220 panel and as a single-plex assay through the Technology Access Program. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease. A definitive diagnosis of Alzheimer’s disease requires evidence of two hallmark pathologies: amyloid plaques and tau neurofibrillary tangles. Until recently, only one of these could be measured in blood: pTau-217, which serves as an indicator of amyloid pathology. However, a positive pTau-217 result alone is insufficient for a confirmatory diagnosis, as many individuals with amyloid accumulation have not yet developed tau tangles. Historically, measuring tau tangle burden required tau PET imaging, a method that is accurate but expensive and operationally complex. Recent studies have shown that a blood-based eMTBR-tau243 assay, based on mass spectrometry, correlates strongly with tau tangle burden, making it a promising blood-based surrogate for tau PET imaging. Alamar’s NULISA platform delivers a broadly accessible eMTBR-Tau assay that specifically targets the MTBR fragment that is generated by endogenous cleavage at site 256. The highly scalable assay measures eMTBR-Tau at attomolar sensitivity, multiplexed with other key neurodegeneration and neuroinflammation biomarkers from a single low volume sample. Beyond diagnosis, the close association between eMTBR-Tau levels and tau tangle burden may allow researchers to directly measure biological response to tau-targeted therapies and address a critical unmet need for a blood-based biomarker of treatment efficacy. Alamar will showcase eMTBR-Tau data at its workshop at the Alzheimer’s Association International Conference 2026 in London on Tuesday, July 14, where researchers will present performance results and clinical findings from studies using the NULISA platform. The workshop will include presentations covering the assay’s analytical performance, correlation with tau PET imaging, and the ability to stratify patients across Alzheimer’s disease stages. The NULISAseq Neuro 220 Panel with eMTBR-Tau is available now.
공고 • Jun 03Alamar Biosciences Launches Nulisa Dried Blood Spot Extraction KitAlamar Biosciences, Inc. launched the NULISA Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices. Dried blood spot sampling turns a few drops of blood into a dried, ambient-shippable specimen. For proteomics, it has been challenging for researchers to recover protein signals from extremely small sample volumes, across different collection devices, without losing the low-abundance biology they are trying to measure. The NULISA DBS Extraction Kit addresses these challenges with a standardized workflow for multiplex protein measurement from blood samples, collected on remote sampling devices and shipped at ambient temperature. The workflow connects remote sample collection to Alamar’s NULISA technology, enabling ultra-sensitive detection of low-abundance protein biomarkers in non-invasive biofluids. The NULISA platform offers ultra-high sensitivity, high specificity, flexible multiplexing, a broad dynamic range, and automated workflows. In validation studies, Alamar demonstrated 85–95% target detectability across its NULISA CNS and Inflammation panels on most supported microsampling platforms. The combination of the ARGO HT instrument design and the simplified collection and transport of dried blood spot microsamples unlocks proteomics in settings where it hasn't been practical, such as specialty clinics, regional labs, and point-of-care environments. The NULISA DBS Extraction Kit standardizes protein extraction across dried blood spot and dried plasma spot microsamples collected on leading third-party microsampling devices, including Capitainer, Telimmune, Mitra, and Tasso. The NULISA DBS Extraction Kit is now available.
New Risk • May 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$67m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$67m free cash flow). Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$32m net loss in 3 years).
Reported Earnings • May 14First quarter 2026 earnings releasedFirst quarter 2026 results: US$1.74 loss per share. Net loss: US$21.3m (flat on 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.
실시간 뉴스 • May 10Alamar Biosciences Launches Home Fingerstick Kit for Ultra Sensitive Multiplex Proteomics AssaysAlamar Biosciences launched the NULISA Dried Blood Spot (DBS) Extraction Kit, allowing its ultra high-sensitivity, multiplex proteomics assays to run on small fingerstick blood samples collected at home. The kit is designed to support longitudinal and decentralized translational studies in neurology, inflammation and population health. The company positions this DBS capability as a way to make proteomics more accessible for population-based screening programs and remote sample collection. This move pushes Alamar’s platform further into remote and decentralized research workflows, which can matter for adoption by academic centers, contract research groups and potential biopharma partners. Investors may want to watch how quickly the DBS kit is incorporated into real-world studies, since usage levels and reference customers could become key indicators of commercial traction for Alamar’s technology.
공고 • May 01Alamar Biosciences, Inc. to Report Q1, 2026 Results on May 08, 2026Alamar Biosciences, Inc. announced that they will report Q1, 2026 results Pre-Market on May 08, 2026
Seeking Alpha • Apr 19Alamar Biosciences: Looking For An Early DetectionSummary Alamar Biosciences surged 30% post-IPO, driven by enthusiasm for its precision proteomics technology targeting early disease detection. Alamar's revenue nearly tripled to $74M in 2025, with annualized sales multiples now around 12x; losses narrowed but remain substantial. Strong cash reserves and rapid topline growth offset concerns about ongoing losses and operating deleverage. I remain on the sidelines, closely monitoring future topline and bottom-line trends before considering a position. Read the full article on Seeking Alpha
공고 • Apr 18Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million.Alamar Biosciences, Inc. has completed an IPO in the amount of $191.25 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Sponsor Backed Offering